Antibody boosts effectiveness of leukemia treatmentTelemanagementResearchers at the University of Texas M.D. Anderson Cancer Center have been treating a group of 202 patients with CLL with standard chemotherapy plus the monoclonal antibody rituximab. T…
Research Antibody Survey: Creative Biomart Conducted a Survey Among …PR.com (press release)Shirley, NY, August 03, 2013 –(PR.com)– With over 100,000 antibodies available, Creative Biomart conducted the survey to investigate the factors that most ma…
Biogen Idec Inc (BIIB): Biogen Idec Product Pipeline Will Propel It HigherSeeking AlphaThinking in terms of 2015 and later, by then we should also see [assuming FDA approval] revenue from Daclizumab for MS. Daclizumab is already approved to prevent the…
Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma …7thSpace Interactive (press release)Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy inclu…
Rituximab Therapy Effective For ANCA-Associated VasculitisRedOrbitIn an article published today in the New England Journal of Medicine, Immune Tolerance Network (ITN) researchers demonstrated that a single course of rituximab therapy (anti-CD20; Rituxa…
Answers About Rheumatoid Arthritis, Part 3New York TimesThese include small molecules (pills) like methotrexate, leflunomide, tofacitinib and injectable or infusable biologic therapies like abatacept, adalimumab, certolizumab, etanercept, golimumab, ri…
|
Rituximab bei ANCA-Vaskulitis: Premiere einer Transparenz-Studie
Deutsches Ärzteblatt Boston – Eine randomisierte Studie in einer eher seltenen klinischen Indikation könnte nicht nur den Betroffenen mit ANCA-assoziierter Vaskulitis nutzen, für die eine Behandlung mit dem Antikörper Rituximab die bessere Wahl sein könnte. Die Studie im … |
Rituximab therapy effective for ANCA-associated vasculitisPhys.OrgIn an article published today in the New England Journal of Medicine, Immune Tolerance Network (ITN) researchers demonstrated that a single course of rituximab therapy (anti-CD20; Rituxa…
Rituximab noninferior to conventional therapy in ANCA-associated vasculitis …2 Minute Medicine1. At 18 months, patients with ANCA-associated vasculitis treated with one course of rituximab had similar outcomes in terms of inducing remission when comp…
|
Rituximab Equally Effective for Remission of Vasculitis
Monthly Prescribing Reference (HealthDay News) – Rituximab is as effective as conventional immunosuppressive therapy in maintaining remission in patients with severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, according to a study published in the Aug. 1 issue … Rituximab noninferior to conventional therapy in ANCA-associated vasculitis …2 Minute Medicine |